Login to Your Account

Taiho reports positive results from phase III trial of mCRC candidate

By Catherine Makino
Contributing Writer

Monday, June 30, 2014
TOKYO – Japan's Taiho Oncology Inc. reported positive results from a global phase III trial of its oral combination anticancer drug TAS-102 (trifluridine and tipiracil hydrochloride) in refractory metastatic colorectal cancer (mCRC).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription